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ABSTRAK 
 
Timoma merangkumi 1% dari keseluruhan kanser mediastinum dan jarang berlaku 
pada kanak-kanak. Secara tipikal, kanser ini adalah agresif dan kadar sembuh adalah 
rendah. Rawatan semasa untuk timoma invasif meliputi pelbagai disiplin. Seorang pe-
sakit berumur 16 tahun telah di diagnosa dengan kanser timoma invasif. Pesakit ini 
telah berjaya dirawat dengan kimoterapi di ikuti dengan pembedahan dan radioterapi. 
Setakat ini, pesakit berada dalam keadaan ‘remission’ yang berterusan selama 6 ta-
hun selepas tamat rawatan. 
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ABSTRACT  
 
Thymomas comprise about 1% of all mediastinal tumours and are rare in children. 
Typically, these tumours are aggressive, with a poor outcome. The current treatment of 
invasive thymoma is often multidisciplinary. We report a 16-year-old boy with invasive 
thymoma who was successfully treated with systemic chemotherapy, surgical 
resection and irradiation. The patient has been in continuous remission for 6 years 
without radiographic evidence of tumour recurrence. 
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INTRODUCTION 
 
Primary thymic lesions such as thymic 
cyts, hyperplasia, carcinoma, and thy-
momas comprise approximately 2-3% of 
all pediatric mediastinal tumours 
(Grosfeld 1994). Thymoma is a tumour 
originating within the epithelial cells of 
the thymus. Patients can present with 
chest pain, cough, dyspnoea, dysphagia, 
hoarseness, superior vena cava syn-
drome or paraneoplastic syndrome in-
cluding myasthenia gravis, pure red cell 
aplasia, or acquired hypogammaglobuli-
naemia, and connective tissue disease 
disorders. Most patients are asympto-
matic. Thymoma can generally be cate-
gorised as non-invasive (Stage I) and 
invasive (Stage II-IV) (Masaoka et al. 
1981). Treatment of thymoma includes 
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surgery, chemotherapy, and irradiation. 
Surgical resection is the treatment of 
choice for stage I and stage II tumours. 
In more advanced diseases, systemic 
therapy has shown to give a response 
rate of 50% to 80% (Thomas et al. 1999). 
Therefore, a multimodal therapy is often 
use for the treatment of patients with ad-
vanced thymoma. Stage of the tumour is 
an independent prognostic factor for sur-
vival. 
 
CASE REPORT  
 
A 16-year-old boy was evaluated for 
cough and chest pain. His past medical 
history was unremarkable. On physical 
examination, the patient showed signs of 
mild superior vena cava (SVC) obstruc-
tion, with decreased right chest breath 
sounds. Other physical examination 
findings were normal. An initial chest X-
ray showed a huge mass in the anterior 
mediastinum. Computerized tomography 
(CT) of the thorax showed an anterior 
mediastinal mass with a diameter of 
6x10x11cm that abutted the great ves-
sels and had posteriorly displaced and 
compressed the SVC (Figure 1). The pa-
tient underwent a CT-guided percutane-
ous biopsy of the mediastinum mass as it 
was considered inoperable. Histopatho-
logical examination revealed a neoplasm 
composed of epithelial cells with sur-
rounding lymphoplasmacytic infiltration 
(Figure 2). The neoplastic epithelial cells 
display round to oval vesicular neuclei. 
Immunohistochemically, the neoplastic 
cells were positive for cytokeratin and 
negative for LCA, vimentin, and S-100, 
confirming the diagnosis of thymoma.  
Neoadjuvant chemotherapy was started 
to improve resectability of the tumour 
mass. A chemotherapy protocol contain-
ing cisplatin (50mg/m2/day, for 1 day), 
cyclophosphamide (500mg/m2/day, for 1 
day), and doxorubicin (50mg/m2/day, for 
2 days) was given and repeated every 21 
days. After 3 cycles of chemotherapy, 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: CT of thorax showed an anterior medias-
tinum mass with a diameter of 6x10x11cm that 
abutted the great vessels and posteriorly displaced 
and compressed the SVC. 
 
about 50% reduction in tumour size was 
observed on a repeat CT scan of the tho-
rax (mass size: 5.4x4.6x7.5cm). Subse-
quently, he was scheduled for a tumour 
excision, however, the surgery was per-
formed after the 4th cycle of chemothe-
rapy. At the time of median sternotomy, 
the mass was densely adhered to the 
underlying pericardium, brachio-cephalic 
vein, SVC, and right upper lobe of the 
lung. The tumour had completely en-
cased the right phrenic nerve and had 
infiltrated the wall of the SVC anterolate-
rally and the wall of the brachio-cephalic 
vein anteriorly. Incomplete resection of 
the tumour was performed together with 
resection of the involved pericardium. A 
small rim of the tumour tissue that had 
infiltrated the SVC and the brachio-ce-
phalic vein walls could not be excised. 
Final pathology showed thymoma with 
unclear margins, consistent with the 
World Health Organization (WHO) classi-
fication of thymoma type B2 and the Ma-
saoka classification of stage III.   
Post-operatively the patient received 
two cycles of chemotherapy; however, a 
residual tumour of 2.0x1.0x0.5cm was 
seen on a repeat CT scan of thorax. 
Subsequently, the patient was treated 
with 30Gy radiotherapy in 15 fractions at 
2.0 Gy per fraction to the tumour area 
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Figure 2: Section shows foci of neoplastic epithelial cells with surrounding lymphoplasmacytic cell infiltration. 
These neoplastic epithelial cells display round to oval vesicular nuclei and some with distinct nucleolus (He-
matoxylin and eosin stain, x100). 
 
followed by boosts of 16Gy in 8 fractions 
at 2.0 Gy per fraction over a period of 4 
weeks. The tumour had cleared on re-
peat CT scan of thorax at the end of the 
treatment. The patient has been in re-
mission for 6 years without radiographic 
evidence of tumour recurrence. 
 
DISCUSSION 
 
Thymoma is uncommon in children. 
Therefore, it is important to recognise 
this tumour as distinct from others like 
mediastinal teratoma, lymphoma, malig-
nant histiocytoma and Ewing sar-
coma/primitive neuroectodermal tumour. 
Most thymomas are confined to the me-
diastinum at the time of diagnosis. Dis-
tant metastasis is rare. 
The widely accepted staging system in 
use for thymoma is that proposed by Ma-
saoka et al. (1981), based on a post-
operative staging procedure, since cap-
sular invasion, a key component of this 
staging system, is best evaluated by pa-
thologic examination. Recently, the WHO 
classification of thymic tumours (Rosai & 
Sobin 1999) based on the histological 
assessment of the morphology of the 
neoplastic epithelial cells has received 
increasing acceptance, and it has been 
shown to be of prognostic significance 
(Chen et al. 2002; Kondo et al. 2004).  
Thymomas are classified as type A, AB, 
and B in the WHO classification, and ex-
hibit organotypic (thymus-like) architec-
tural features. Nevertheless, Kim et al. 
(2010) reported that the prognostic re-
levance among type B thymoma subtypes 
is still controversial. They did not find any 
significant differences in the incidence of 
recurrence and survival among the three 
subtypes of type B thymomas. Tumour 
recurrence was significantly associated 
with advanced Masaoka stages. Some 
have shown that patients with type B3 
thymomas have worse prognoses than 
those with type B2 thymomas (Okumura 
et al. 2002; Nakagawa et al. 2003), 
whereas others have reported a similar 
survival rate between these two groups 
(Chen et al. 2002; Ströbel et al. 2004). 
Therefore, Masaoka stage should always 
be considered when predicting prognosis 
and planning treatment, including adjuvant 
treatment for patients with type B thy-
momas. 
Surgical resection is the mainstay of 
treatment in patients with resectable dis-
ease (Yagi et al. 1996; Wang et al. 
1992). The extent of surgical resection 
remains the most important prognostic 
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factor for predicting tumour relapse 
(Singhal et al. 2003). Dhall et al. (2004) 
reported two children with completely en-
capsulated thymoma who were suc-
cessfully treated with surgery alone, and 
remain free of disease 3 years after sur-
gery. However, multimodal therapy con-
sisting of chemotherapy, radiotherapy, 
and/or surgery is recommended for any 
incompletely resected “high-risk” thy-
moma, locally advanced or metastatic 
thymoma (Chahinian et al. 1981; Ströbel 
et al. 2005). It has been shown that mul-
timodal treatment of patients with 
neoadjuvant chemotherapy, and surgery, 
followed by additional adjuvant chemo-
therapy plus radiotherapy, may improve 
the survival of patients with locally ad-
vanced thymoma (Venuta et al. 1997; 
Hassan & Seoud 2009). In addition, in-
duction chemotherapy may be effective 
in downstaging thymoma, allowing pa-
tients initially thought not to be surgical 
candidates to undergo resection.  
Our patient had advanced tumour stage 
III Masaoka classification. The benefit of 
multimodal therapy was demonstrated in 
our patient as the patient showed a par-
tial response to the induction chemothe-
rapy improving the resectability of the 
mass during surgery. Although "debulk-
ing" or subtotal resection have been re-
ported for invasive thymoma, most mod-
ern day series have demonstrated long 
term survival correlating best with com-
plete surgical removal. Therefore, we 
believe most surgeons would likely per-
form en bloc great vein and phrenic 
nerve resection in this case.  Removal of 
one brachiocephalic vein is usually well 
tolerated and there are a number of 
techniques to reconstruct the SVC. Di-
aphragmatic plication could also be per-
formed to improve breathing mechanics 
after phrenic nerve removal, which may 
be dysfunctional from tumour involve-
ment to begin with. Subsequently, the 
postoperative adjuvant chemotherapy
and radiotherapy further help to clear the 
tumour in this patient. Previously, Shin et 
al. (1998) reported that induction che-
motherapy consisted of cyclophospha-
mide, doxorubicin, and cisplatin was 
given to patients with unresectable stage 
III and IV thymoma. Out of 11 patients 
initially thought to be unresectable, nine 
were able to undergo resection. All nine 
patients were given additional postoper-
ative adjuvant chemotherapy and radio-
therapy. Out of these patients, seven 
were disease-free at a median follow-up 
period of 43 months. Yokoi et al. (1992) 
reported a successful treatment with 
preoperative/postoperative cisplatin and 
doxorubicin, in addition to postoperative 
radiotherapy in a patient with a locally 
advanced thymoma invading the heart 
and great vessels. Macchiarini et al. 
(1991) reported that four patients with 
clinical stage III thymoma received three 
cycles of cisplatin, epirubicin, and etopo-
side before surgery, and later achieved a 
complete remission. Rea et al. (1993) 
reported that 16 patients with stage III 
and IVa disease were treated with a dox-
orubicin, cisplatin, vincristine, and cyclo-
phosphamide regimen every three weeks 
for three to four cycles. After chemothe-
rapy, surgery was performed, and if resi-
dual disease was present, postoperative 
radiation therapy was given. Patients 
with a complete remission received three 
additional cycles of chemotherapy. The 
authors demonstrated seven complete 
and five partial responses and a pro-
jected two-year survival rate of 80%. 
Loehrer et al. (1997) reported a response 
rate of around 70% in 23 patients with 
stage III thymoma who received chemo-
radiotherapy. The progression-free and 
overall survival rates at five years were 
54% and 52% respectively.   
As demonstrated in this patient, the use 
of multimodal therapy in locally advanced 
thymoma was effective, significantly de-
creasing the tumour size, thus improving
Invasive thymoma in children  Med & Health 2010; 5(1): 49-54 
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the patient’s surgical outcome, and over-
all contributed to a good long-term out-
come. 
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